Gehang Ju

Abstract Escitalopram is widely used to treat major depressive disorder, yet drug exposure varies substantially across patients, causing the inadequate response or toxicity probability. Individualized dosing supported by therapeutic drug monitoring and published population pharmacokinetic models is promising, but independent evaluation of existing models and clinically usable decision-support tools remains limited.

Back to Journals » Drug Design, Development and Therapy » Volume 20 Authors Yan K, Gao R, Ju G, Shao Q, Wang N Received 6 January 2026 Accepted for publication 10 April 2026 Published 15 May 2026 Volume 2026:20 589767 DOI https://doi.org/10.2147/DDDT.S589767 Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Dr Muzammal Hussain Keyu Yan,1 Ruomei Gao,2 Gehang Ju,3,4 Qing Shao,1 Na Wang1 1Department of Pharmacy, Xi’an...

INTRODUCTION Over the past two decades, the incidence of invasive fungal infections (IFIs) has steadily increased. IFIs have become a prevalent hospital-acquired infection, 50% of which occur in patients in the pediatric intensive care unit (PICU) (1, 2). Caspofungin, the first echinocandin approved for treating IFIs, is effective against infections caused by Candida and Aspergillus species.